NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院

Clinical TrialsSearch results

Search

Number of results: 443
  • Recruitment status
  • Title of the study
  • Health Condition
  • Primary sponsor
  • Date of registration
  • Completed

  • TORG1936 / AMBITIOUS study
  • Advanced / recurrent Non-small cell lung cancer with idiopathic interstitial pneumonia
  • KATO Terufumi
  • 2019-08-27
  • Recruiting

  • Multi-center observational study and present status survey for the establishment of the standard method for the long-term use of HAL.
  • The subjects will consist of patients with reduced walking function due to slowly progressive neurological/muscular diseases. HAL for medical use (lower limb type) is indicated for the following slowly progressive neurological/muscular diseases:spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), distal myopathy, inclusion body myositis (IBM), congenital myopathy, and muscular dystrophy. Patients who were diagnosed with one of the 8 diseases and require walking assistance or aids will be included as subjects. In addition, even patients who were not definitively diagnosed with one of the above 8 diseases but use HAL in daily medical practice at the attending physician's discretion will be included as subjects.
  • Takashi Nakajima
  • 2019-08-02
  • Recruiting

  • Multi-center observational study and present status survey for the establishment of the standard method for the long-term use of HAL.
  • The subjects will consist of patients with reduced walking function due to slowly progressive neurological/muscular diseases. HAL for medical use (lower limb type) is indicated for the following slowly progressive neurological/muscular diseases:spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), distal myopathy, inclusion body myositis (IBM), congenital myopathy, and muscular dystrophy. Patients who were diagnosed with one of the 8 diseases and require walking assistance or aids will be included as subjects. In addition, even patients who were not definitively diagnosed with one of the above 8 diseases but use HAL in daily medical practice at the attending physician's discretion will be included as subjects.
  • Takashi Nakajima
  • 2019-08-02
  • Recruiting

  • Multi-center observational study and present status survey for the establishment of the standard method for the long-term use of HAL.
  • The subjects will consist of patients with reduced walking function due to slowly progressive neurological/muscular diseases. HAL for medical use (lower limb type) is indicated for the following slowly progressive neurological/muscular diseases:spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), distal myopathy, inclusion body myositis (IBM), congenital myopathy, and muscular dystrophy. Patients who were diagnosed with one of the 8 diseases and require walking assistance or aids will be included as subjects. In addition, even patients who were not definitively diagnosed with one of the above 8 diseases but use HAL in daily medical practice at the attending physician's discretion will be included as subjects.
  • Takashi Nakajima
  • 2019-08-02
  • Recruiting

  • Multi-center observational study and present status survey for the establishment of the standard method for the long-term use of HAL.
  • The subjects will consist of patients with reduced walking function due to slowly progressive neurological/muscular diseases. HAL for medical use (lower limb type) is indicated for the following slowly progressive neurological/muscular diseases:spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), distal myopathy, inclusion body myositis (IBM), congenital myopathy, and muscular dystrophy. Patients who were diagnosed with one of the 8 diseases and require walking assistance or aids will be included as subjects. In addition, even patients who were not definitively diagnosed with one of the above 8 diseases but use HAL in daily medical practice at the attending physician's discretion will be included as subjects.
  • Takashi Nakajima
  • 2019-08-02
  • Recruiting

  • Multi-center observational study and present status survey for the establishment of the standard method for the long-term use of HAL.
  • The subjects will consist of patients with reduced walking function due to slowly progressive neurological/muscular diseases. HAL for medical use (lower limb type) is indicated for the following slowly progressive neurological/muscular diseases:spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), distal myopathy, inclusion body myositis (IBM), congenital myopathy, and muscular dystrophy. Patients who were diagnosed with one of the 8 diseases and require walking assistance or aids will be included as subjects. In addition, even patients who were not definitively diagnosed with one of the above 8 diseases but use HAL in daily medical practice at the attending physician's discretion will be included as subjects.
  • Takashi Nakajima
  • 2019-08-02
  • Recruiting

  • Multi-center observational study and present status survey for the establishment of the standard method for the long-term use of HAL.
  • The subjects will consist of patients with reduced walking function due to slowly progressive neurological/muscular diseases. HAL for medical use (lower limb type) is indicated for the following slowly progressive neurological/muscular diseases:spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), distal myopathy, inclusion body myositis (IBM), congenital myopathy, and muscular dystrophy. Patients who were diagnosed with one of the 8 diseases and require walking assistance or aids will be included as subjects. In addition, even patients who were not definitively diagnosed with one of the above 8 diseases but use HAL in daily medical practice at the attending physician's discretion will be included as subjects.
  • Takashi Nakajima
  • 2019-08-02
  • Other

  • NEJ043
  • Non-sequamous non-small cell lung cancer
  • Kikuchi Toshiaki
  • 2019-08-01
  • Recruiting

  • RICE study 2
  • Chronic kidney disease
  • Narita Ichiei
  • 2019-07-26

Progress situation









The subject of age and gender

Sex



Age